5月12日 - ** 制药商Invivyd IVVD.O股价盘前上涨11.4%至72美分
** 该公司称已启动麻疹单克隆抗体测试发现项目
** 单克隆抗体是实验室制造的蛋白质，可模拟免疫系统抵御病毒等有害病原体的能力
** IVVD表示："目标是在2025年确定临床前单克隆抗体候选物；预计在年底前提供最新进展情况"。
** 目前还没有针对麻疹的抗病毒疗法；据美国疾病预防控制中心称，麻疹疫苗接种两剂后的有效率为 97
** 5月9日的联邦数据显示，美国麻疹病例五年来首次突破1000 (link)
** 截至上次收盘，股价年累计上涨 45.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.